Literature DB >> 3955309

Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.

V Pierce, N B Shepperson, M H Todd, J F Waterfall.   

Abstract

The cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin have been compared with those of prazosin in the anaesthetized rat. The effects of autonomic blockade on heart rate responses evoked by these two agents and their effects on blood pressure and heart rate after peripheral or central administration have been compared. Cumulative administration of indoramin (0.8-25.6 mg kg-1 i.v.) evoked significant decreases in arterial blood pressure and a concomitant bradycardia. Pithing or autonomic blockade, by pretreatment with a combination of practolol and bilateral vagotomy, prevented the bradycardia evoked by indoramin (0.8-3.2 mg kg-1 i.v.). Atropine sulphate pretreatment abolished the bradycardia until a cumulative dose of 25.6 mg kg-1(i.v.) of indoramin had been reached. Bilateral vagotomy, intravenous administration of atropine methylnitrate or practolol pretreatment attenuated the bradycardia. Prazosin (0.02-0.64 mg kg-1 i.v.) evoked a fall in arterial blood pressure of similar magnitude to that observed following indoramin. A bradycardia was evoked only at a relatively high dose (0.64 mg kg-1 i.v.). Intracisternal injection of indoramin or prazosin evoked bradycardia and hypotension at a dose which had no effect after intravenous injection (25 micrograms). Intracerebroventricular injection of indoramin (25 micrograms) had no significant effect on heart rate or blood pressure compared to control values, whereas prazosin (25 micrograms) evoked a significant tachycardia and hypotension. It is concluded that the bradycardia evoked by indoramin in the rat is not due to a direct action on the heart except possibly at high doses. Central alpha 1-adrenoceptor blockade, possibly in the brainstem region, results in a bradycardia and this may explain the lack of reflex tachycardia following the administration of indoramin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3955309      PMCID: PMC1916533          DOI: 10.1111/j.1476-5381.1986.tb10834.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS.

Authors:  A HERZ; H TESCHEMACHER; A HOFSTETTER; H KURZ
Journal:  Int J Neuropharmacol       Date:  1965-07

2.  Central and peripheral contribution to the antihypertensive action of indoramin.

Authors:  T Baum; A T Shropshire
Journal:  Eur J Pharmacol       Date:  1975-05       Impact factor: 4.432

3.  Studies relating to the antihypertensive and antidysrhythmic action of indoramin.

Authors:  T Baum; A T Shropshire; D K Eckfeld; N Metz; J L Dinish; J R Peters; F Butz; M I Gluckman
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-08

4.  Autonomic blocking properties of Wy 21901.

Authors:  B J Alps; M Hill; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

Review 5.  Cardiac alpha adrenoceptors.

Authors:  B G Benfey
Journal:  Can J Physiol Pharmacol       Date:  1980-10       Impact factor: 2.273

6.  The treatment of arterial hypertension with a new alpha-blocker, indoramin.

Authors:  R Carballo; L Conde; M Lapelle; J Suarez
Journal:  Curr Med Res Opin       Date:  1974       Impact factor: 2.580

7.  The blood pressure lowering effects of intravenous versus intracerebroventricular prazosin in anaesthetised cats.

Authors:  A G Roach; R Gomeni; M Mitchard; J P Nicolas; I Cavero
Journal:  Eur J Pharmacol       Date:  1978-06-01       Impact factor: 4.432

8.  Quantitative analysis on isolated organs of the autonomic blocking properties of indoramin hydrochloride (Wy 21901).

Authors:  B J Alps; M Hill; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

9.  Correlation between decreased heart rate and central inhibition of sympathetic discharge after prazosin administration in the spontaneously hypertensive rat.

Authors:  B Persson; T Yao; P Thorén
Journal:  Clin Exp Hypertens       Date:  1981       Impact factor: 1.749

Review 10.  Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents.

Authors:  S Z Langer; I Cavero; R Massingham
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.